Will Intensity Therapeutics stock go up?

According to Danelfin AI, Intensity Therapeutics has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (46.60%) is -4.22% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Intensity Therapeutics stock?

The Intensity Therapeutics target price is $4.26 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Intensity Therapeutics stock right now?

Intensity Therapeutics has today a Sell rating (AI Score 3/10), according to Danelfin AI. Its probability of beating the market in 3 months (46.60%) is -4.22% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Intensity Therapeutics stock is a good buy .

Is Intensity Therapeutics undervalued right now?

Based on analysts, the average price target downside for Intensity Therapeutics is 0.00% (1Y). According to Danelfin AI, Intensity Therapeutics has today an AI Score of 3/10 (Sell Rating).

What was the price range of Intensity Therapeutics stock over the past 12 months?

The Intensity Therapeutics stock price range over the past 12 months has been $3.62 - $33.

What is going on with Intensity Therapeutics stock in the last 3 months?

The Intensity Therapeutics stock performance in the last quarter has been -25.12%.

Does Intensity Therapeutics offer dividend payments?

No, Intensity Therapeutics does not currently pay dividends.

What is the current market capitalization of Intensity Therapeutics?

Intensity Therapeutics's market cap is $11.46M, as of 2026-07-03 08:00.

Intensity Therapeutics Inc (INTS) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

INTS AI-Powered Stock Analysis

AI Score Explanation

AI Score

Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Intensity Therapeutics Inc today receives an AI Score of 3/10, which translates to a Sell rating. The stock has a 47% probability of outperforming the market in the next 3 months, which is 4% lower than the average probability of any stock (51%). Among the top positive contributors, Average Volume (3m) (in the bottom 10%) adds +0.70% to the probability, while Performance (YTD) (bottom 10%) adds +0.57%, and Alpha 1Y (bottom 20%) adds +0.53%. On the negative side, the top detractors include Institutional Ownership (bottom 20%) reducing probability by -1.08%, Chart Pattern (504d) by -1.00%, and the Fear & Greed Index (value 31) by -0.76%. Notable data points include a Beta of 3.0 (top 10%), indicating high volatility, which detracts -0.66% from the probability. The Distance from KAMA (20d) is in the top 10%, suggesting the stock may be overbought, reducing probability by -0.60%. The Normalized Average True Range (50d) is in the top 20%, reflecting high volatility, also a detractor. On the positive side, the stock's poor year-to-date performance (-58.5%, bottom 10%) and negative alpha metrics (Alpha 1Y bottom 20%, Alpha 6M bottom 10%) actually contribute positively, as the model sees potential for mean reversion. Overall, the combination of high volatility, low institutional ownership, and bearish chart patterns outweighs the potential rebound signals, resulting in a low AI Score and a Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Size & Liquidity+0.96%
Company size and trading liquidity
Earnings Quality+0.25%
Stability and reliability of reported earnings
Valuation+0.01%
How the stock is priced relative to its fundamentals

Sentiment-2.05%
How analysts and the market view the stock
Momentum-1.98%
Direction and strength of recent price movements
Volatility-1.11%
How much the stock price tends to fluctuate
Financial Strength-0.30%
Balance sheet strength and financial resilience

INTS probability advantage of beating the market (3M):

-4.22%

AI Score

Sell

Intensity Therapeutics (INTS) has an AI Score of 3/10 (Sell) because, according to an overall analysis, it has a probability advantage of -4.22% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of INTS (46.60%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
INTS probability advantage of beating the market (3M)-4.22%
INTS probability of beating the market (3M)46.60%

INTS probability advantage of beating the market (3M): -4.22%

The AI-powered overall analysis of Intensity Therapeutics (INTS) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of INTS:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Institutional Ownership	5.26%		-1.08%
Technical	Chart Pattern (504d)	figure_6	N/A	-1.00%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.76%
Technical	Average Volume (3m)	$33.66K	N/A	+0.70%
Technical	Beta	3		-0.66%
Technical	Chart Pattern (180d)	figure_9	N/A	-0.61%
Technical	Distance from KAMA (20d)	0.10%		-0.60%
Technical	Performance (YTD)	-0.58%	N/A	+0.57%
Technical	Alpha 1Y	-0.65%		+0.53%
Technical	Alpha 6M	-0.63%	N/A	-0.52%
Technical	Upgrade to unlock			-0.51%
Technical	Upgrade to unlock			-0.48%
Sentiment	Upgrade to unlock			-0.47%
Fundamental	Upgrade to unlock			+0.45%
Fundamental	Upgrade to unlock			-0.44%

Rest of Alpha Signals: +0.66%

INTS probability advantage of beating the market (3M)Total:-4.22%
INTS AI Score

Significant changes Vs previous day

INTS Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$4.26
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

INTS Proven Sell Signal & Price Forecast

This is the price chart for INTS from January 2, 2026 until today. The chart indicates, in red, the 68 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

INTS Average Past Performance & Loss Rate

Three months after its 213 Sell signals since July 2026, INTS had an average performance of xxxxxxx and a xxxxxx Loss rate (negative performance).

213 Past INTS Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-55.37%
Average Alpha				-75.71%
Loss Rate (% Negative Perf.)				100.00%
% Negative Alpha				100.00%

INTS Frequently Asked Questions

Will Intensity Therapeutics stock go up?
According to Danelfin AI, Intensity Therapeutics has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (46.60%) is -4.22% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Intensity Therapeutics stock?
Is it a good time to buy, sell, or hold Intensity Therapeutics stock right now?
Is Intensity Therapeutics undervalued right now?
What was the price range of Intensity Therapeutics stock over the past 12 months?
What is going on with Intensity Therapeutics stock in the last 3 months?
Does Intensity Therapeutics offer dividend payments?
What is the current market capitalization of Intensity Therapeutics?

Intensity Therapeutics Inc Company Profile

Operating as a clinical-stage biotechnology entity, Intensity Therapeutics, Inc. primarily leads in unearthing, cultivating, and introducing cancer medication within the United States. The front runner among the company's product prototypes is INT230-6 - currently under advanced human clinical examination for counteracting resistant solid tumors including soft tissue sarcoma, presently in Phase 3 trials. Moreover, the drug is also under Phase 2 scrutiny for managing neoadjuvant and metastatic triple negative breast cancer. Established as a corporate organization in 2012, Intensity Therapeutics presently holds its headquarters in Shelton, Connecticut.

Sector:
Country:United States
Industry:
Address:1 Enterprise Drive, Suite 430, Shelton
Employees:6
Website:intensitytherapeutics.com

Pros

Proprietary intellectual property for novel compounds

High unmet medical need in oncology

Potential for accelerated regulatory pathways

Platform technology applicability across cancer types

Premium pricing potential for successful therapies

Cons

High clinical trial failure rates in oncology

Substantial capital intensity for drug development

Lengthy and unpredictable regulatory approval processes

Reliance on intellectual property protection

Single lead product candidate dependency

Pros

Cons

Company

AI Score

Compare

PHIOPhio Pharmaceuticals Corp

IBRXImmunitybio Inc

ONCYOncolytics Biotech Inc

BCTXBriacell Therapeutics Corp

IOVAIovance Biotherapeutics Inc

Company

AI Score

Compare

INTS Top 10 Industry Stocks

Biotechnology

	Company	AI Score	Compare
1	COGTCogent Biosciences Inc
2	IMNMImmunome Inc
3	VRDNViridian Therapeutics Inc
4	ZYMEZymeworks Inc
5	RNAAvidity Biosciences Inc
6	EBSEmergent BioSolutions Inc
7	ACRVAcrivon Therapeutics Inc
8	CGONCG Oncology Inc
9	IONSIonis Pharmaceuticals Inc
10	ZLABZai Lab Ltd

	Company	AI Score	Compare

Company

AI Score

Compare

COGTCogent Biosciences Inc

Company

AI Score

Compare

INTS Stock AI Analysis High Risk